GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (NSE:JUBLPHARMA) » Definitions » Float Percentage Of Total Shares Outstanding

Jubilant Pharmova (NSE:JUBLPHARMA) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 19, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Jubilant Pharmova Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Jubilant Pharmova's float shares is 0.00 Mil. Jubilant Pharmova's total shares outstanding is 158.40 Mil. Jubilant Pharmova's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Jubilant Pharmova's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Jubilant Pharmova's Institutional Ownership is 10.66%.


Jubilant Pharmova Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Jubilant Pharmova's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/158.40
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jubilant Pharmova Business Description

Industry
Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.

Jubilant Pharmova Headlines

No Headlines